China Resources Pharmaceutical Group (3320.HK)

Executive Summary

China Resources Pharmaceutical Group (CR Pharma, 3320.HK) is a state-backed pharmaceutical conglomerate with an integrated business spanning R&D, manufacturing, distribution, and retail. As a subsidiary of China Resources Group, it commands one of the largest pharmaceutical distribution networks in China and operates a retail pharmacy chain under the CRCare brand. The company's pipeline includes 10 drug candidates, with recent focus on oncology and metabolic diseases. Key assets include Shenfu Injection for acute heart failure and Jinfukang for non-small cell lung cancer, both approved. An ongoing Phase 2 trial of Teniposide for extensive-stage small cell lung cancer (NCT06758700) is recruiting and expected to complete by end-2026. Meanwhile, a fixed-dose combination of Metformin and Empagliflozin for type 2 diabetes is in pre-clinical stages but nearing regulatory submission. CR Pharma's strategic position is bolstered by its state ownership, which provides stability and potential policy tailwinds, such as preferential procurement or consolidation opportunities. However, the company faces challenges from generic competition and pricing pressures in China's healthcare reforms. Overall, CR Pharma offers a diversified exposure to China's pharmaceutical sector with a mix of established commercial products and emerging pipeline catalysts.

Upcoming Catalysts (preview)

• Q4 2026Teniposide Phase 2 interim/final results for ES-SCLC60% success
• Q2 2026Metformin + Empagliflozin FDC regulatory submission or approval in China80% success
• TBDPotential government policy support for state-owned pharmaceutical enterprises50% success